Our current focus is on a therapeutic solution for rheumatoid arthritis,

a product of 8 years of research.

iBio Tech Aps responds to a health problem that millions suffer worldwide. 

Why should we care about rheumatoid arthritis (RA)? Few facts...

  •   Autoimmune diseases as RA cause permanent disability, over 50% RA patients become permanently physically disabled 2-5 years after the disease onset.
  •   Over 20% RA patients do not respond to existing treatment.
  •   It has a prevalence of 9:1 for women vs men.
  •   RA patients live with daily pain and fatigue with a significant impact on physical activity and life quality

This generates a real necessity for developing a solution to treat what we call "poor responders".

Which is the cost of RA?

  •   The annual cost per patient is 15,000-20,000 USD. Overall market estimates more than 100 billion          USD are spent annually worldwide.

  •   Denmark alone spends over 700 mil. DKK annually on ineffective RA management.

With our therapeutic candidate, we will be able to target 20%-6.2 billion USD market, which are ‘’poor responders” to the existing treatments.

Moreover, iBio Tech solution for RA is in fact 35% of the cost for currently used drugs as NSAIDs/DMARDs, and only 15% of the cost for other biologics currently in use.


What distinguishes our solution?

Impact on patients

Currently, patients that suffer RA need to combine different available drugs as treatment for their disease which increases the number of serious side effects that patients suffer.

However, Aptamer - nanoparticle Technology developed by iBio tech Aps can be used as a unique solution that allows treating patients that suffer RA without adding any drugs to the treatment regime.

Thus, this technology would reduce the amount of medication required, having a positive impact on the daily lives of chronic patients.

Moreover, our technology is based on the use of aptamers that do not have any functions in the normal immune response, which makes Aptamer - nanoparticle Technology a first in class for the treatment of RA.

What makes the technology different?

Our technology is based on aptamers which are highly attractive assets having the ability to refold into an active conformation and being able to be synthesized through a more cost-effective method in comparison with antibody therapies. Not only that but also our technology presents...

  •   Unique action mechanism.

  •   Good efficacy, low immunogenicity in cells, and high selectivity.

  •   Potential of technology extension to other autoimmune diseases.

  •   Standard, inexpensive synthetic protocols.

  •   High stability under the storage.

  •   Comparable or lower price than current drugs.


Our therapeutic approach has no side effects and reduces disease activity by 50% over 1-month treatment. While other drugs are developed to treat the symptoms of RA, we can say that our technology is focused on the main problem:


Treat an imbalance in the immune system through the recognition and clearance of overreactive and pro-inflammatory cells and antibodies.

It is now confirmed that autoantibody levels raise with no symptoms up to 10 years prior to the disease onset. Therefore, we are focusing on the early treatment window, to effectively stop and reverse the disease development. Achieving this preventive approach with the novel, low side-effect therapeutics could be a valuable support to patient management.

iBio tech has developed novel diagnostic aptamer tools and therapeutic nanoconjugates that specifically target disease associated to antibodies and cells. With the ultimate goal of helping people with autoimmune diseases as RA in order to increase their quality life.